888-416-9305 info@abterrabio.com

About Us

12

Years in Business

9

Services

4

Technologies

What We Do

Abterra Biosciences is enabling the next-generation of antibody therapeutics.  Our technologies use the latest in next-generation sequencing, mass spectrometry, and machine learning methods to comprehensively map the antibody response to challenge.  We give our partners access to every relevant antibody to meet their project goals.

 

Who We Are

Abterra Biosciences began life as Digital Proteomics LLC, a spin-out of the University of California – San Diego. Founders Pavel Pevzner and Vineet Bafna are professors in the Computer Science and Engineering Department and leading researchers in bioinformatics. Their expertise forms the algorithmic foundation upon which our products and services are built. Read more about our unique solutions and recent product news.

Our Story

Over the Years

^
2009

Founded

Cofounder Pavel Pevzner

Dr Pavel Pevzner

Ronald R. Taylor Professor of Computer Science and Engineering, UCSD

Director of the NIH Center for Computational Mass Spectrometry, UCSD

Cofounder Vineet Bafna

Dr Vineet Bafna

Professor of Computer Science and Engineering, UCSD

Founding Faculty of Halicioglou Data Science Institute, UCSD

^
2012

Valens

Valens enables antibody sequencing and characterization direct from the protein.

^
2016

Quorum

Quorum uses mass spectrometry signatures to identify related molecules including metabolites, glycans, and peptides.

^
2017

Alicanto

Alicanto extends the Valens technology to characterize diverse collections of antibodies derived from a natural immune response.

^
2019

Reptor

Reptor is a flexible, next-generation sequencing powered platform for B-cell receptor sequencing.

^
2021

Abterra Biosciences

Abterra Biosciences was born and continues to deliver innovative antibody sequencing and discovery solutions to our partners.

Abterra Bio logo

San Diego

3030 Bunker Hill Street   
Ste 218
San Diego, CA 92109 USA

(888)416-9305

Subscribe To Our Newsletter!

Don't miss out on the latest case studies, posters, and other news.

You have Successfully Subscribed!